Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma-Reference-Cited by-同舟云学术

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

Published:2005-10-01 Issue:7 Volume:104 Page:1478-1486
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Reardon David A.,Quinn Jennifer A.,Rich Jeremy N.,Desjardins Annick,Vredenburgh James,Gururangan Sridharan,Sathornsumetee Sith,Badruddoja Michael,McLendon Roger,Provenzale James,Herndon James E.,Dowell Jeannette M.,Burkart Jill L.,Newton Herbert B.,Friedman Allan H.,Friedman Henry S.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

3. MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

4. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

5. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repurposing drugs in glioblastoma;New Insights Into Glioblastoma;2023

2. Front-Line Window Therapy with Temozolomide and Irinotecan in Patients with Primary Disseminated Multifocal Ewing Sarcoma: Results of the ISG/AIEOP EW-2 Study;Cancers;2021-06-18

3. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420;International Journal of Radiation Oncology*Biology*Physics;2019-03

4. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation;Annals of Oncology;2018-08

5. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma;Neuro-Oncology;2017-10-12